Your browser doesn't support javascript.
loading
Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts.
Aubert, Carole E; Floriani, Carmen; Bauer, Douglas C; da Costa, Bruno R; Segna, Daniel; Blum, Manuel R; Collet, Tinh-Hai; Fink, Howard A; Cappola, Anne R; Syrogiannouli, Lamprini; Peeters, Robin P; Åsvold, Bjørn O; den Elzen, Wendy P J; Luben, Robert N; Bremner, Alexandra P; Gogakos, Apostolos; Eastell, Richard; Kearney, Patricia M; Hoff, Mari; Le Blanc, Erin; Ceresini, Graziano; Rivadeneira, Fernando; Uitterlinden, André G; Khaw, Kay-Tee; Langhammer, Arnulf; Stott, David J; Westendorp, Rudi G J; Ferrucci, Luigi; Williams, Graham R; Gussekloo, Jacobijn; Walsh, John P; Aujesky, Drahomir; Rodondi, Nicolas.
Afiliação
  • Aubert CE; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Floriani C; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Bauer DC; Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, California 94143.
  • da Costa BR; Institute of Primary Health Care (Berner Institut für Hausarztmedizin), University of Bern, 3012 Bern, Switzerland.
  • Segna D; Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, 3010 Bern, Switzerland.
  • Blum MR; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Collet TH; Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Fink HA; Service of Endocrinology, Diabetes, and Metabolism, University Hospital of Lausanne, 1011 Lausanne, Switzerland.
  • Cappola AR; Geriatric Research Education and Clinical Center, Veterans Affairs Health Care System, Minneapolis, Minnesota 55417.
  • Syrogiannouli L; Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455.
  • Peeters RP; University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104.
  • Åsvold BO; Institute of Primary Health Care (Berner Institut für Hausarztmedizin), University of Bern, 3012 Bern, Switzerland.
  • den Elzen WPJ; Departments of Internal Medicine and Epidemiology, Erasmus University Rotterdam, 3062 Rotterdam, The Netherlands.
  • Luben RN; Department of Public Health and Nursing, Norges teknisk-naturvitenskapelige universitet, Norwegian University of Science and Technology, N-7491 Trondheim, Norway.
  • Bremner AP; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, N-7006 Trondheim, Norway.
  • Gogakos A; Leiden University Medical Center, Department of Clinical Chemistry and Laboratory Medicine, 2300 RC Leiden, The Netherlands.
  • Eastell R; Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 0SR, United Kingdom.
  • Kearney PM; School of Population Health, University of Western Australia, Crawley, Perth, Western Australia 6009, Australia.
  • Hoff M; Molecular Endocrinology Laboratory, Hammersmith Campus, Department of Medicine, Imperial College London, London W12 0NN, United Kingdom.
  • Le Blanc E; Department of Oncology and Metabolism, University of Sheffield, Sheffield, South Yorkshire S10 2TN, United Kingdom.
  • Ceresini G; Department of Epidemiology and Public Health, University College Cork, T12 PX46 Cork, Ireland.
  • Rivadeneira F; Department of Public Health and Nursing, Norges teknisk-naturvitenskapelige universitet, Norwegian University of Science and Technology, N-7491 Trondheim, Norway.
  • Uitterlinden AG; Levanger Hospital, Nord-Trøndelag Hospital Trust, 7600 Levanger, Norway.
  • Khaw KT; Center for Health Research NW, Kaiser Permanente, Portland, Oregon 97277.
  • Langhammer A; Department of Clinical and Experimental Medicine, Geriatric Endocrine Unit, University Hospital of Parma, 43126 Parma, Italy.
  • Stott DJ; Departments of Internal Medicine and Epidemiology, Erasmus University Rotterdam, 3062 Rotterdam, The Netherlands.
  • Westendorp RGJ; Departments of Internal Medicine and Epidemiology, Erasmus University Rotterdam, 3062 Rotterdam, The Netherlands.
  • Ferrucci L; School of Population Health, University of Western Australia, Crawley, Perth, Western Australia 6009, Australia.
  • Williams GR; Department of Public Health and Nursing, Norges teknisk-naturvitenskapelige universitet, Norwegian University of Science and Technology, N-7491 Trondheim, Norway.
  • Gussekloo J; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G31 2ER, United Kingdom.
  • Walsh JP; Department of Public Health, Center for Health Aging, University of Copenhagen, 1004 Copenhagen, Denmark.
  • Aujesky D; National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224.
  • Rodondi N; Department of Oncology and Metabolism, University of Sheffield, Sheffield, South Yorkshire S10 2TN, United Kingdom.
J Clin Endocrinol Metab ; 102(8): 2719-2728, 2017 08 01.
Article em En | MEDLINE | ID: mdl-28482002
ABSTRACT
Context Hyperthyroidism is associated with increased fracture risk, but it is not clear if lower thyroid-stimulating hormone (TSH) and higher free thyroxine (FT4) in euthyroid individuals are associated with fracture risk.

Objective:

To evaluate the association of TSH and FT4 with incident fractures in euthyroid individuals.

Design:

Individual participant data analysis.

Setting:

Thirteen prospective cohort studies with baseline examinations between 1981 and 2002.

Participants:

Adults with baseline TSH 0.45 to 4.49 mIU/L. Main Outcome

Measures:

Primary outcome was incident hip fracture. Secondary outcomes were any, nonvertebral, and vertebral fractures. Results were presented as hazard ratios (HRs) with 95% confidence interval (CI) adjusted for age and sex. For clinical relevance, we studied TSH according to five categories 0.45 to 0.99 mIU/L; 1.00 to 1.49 mIU/L; 1.50 to 2.49 mIU/L; 2.50 to 3.49 mIU/L; and 3.50 to 4.49 mIU/L (reference). FT4 was assessed as study-specific standard deviation increase, because assays varied between cohorts.

Results:

During 659,059 person-years, 2,565 out of 56,835 participants had hip fracture (4.5%; 12 studies with data on hip fracture). The pooled adjusted HR (95% CI) for hip fracture was 1.25 (1.05 to 1.49) for TSH 0.45 to 0.99 mIU/L, 1.19 (1.01 to 1.41) for TSH 1.00 to 1.49 mIU/L, 1.09 (0.93 to 1.28) for TSH 1.50 to 2.49 mIU/L, and 1.12 (0.94 to 1.33) for TSH 2.50 to 3.49 mIU/L (P for trend = 0.004). Hip fracture was also associated with FT4 [HR (95% CI) 1.22 (1.11 to 1.35) per one standard deviation increase in FT4]. FT4 only was associated with any and nonvertebral fractures. Results remained similar in sensitivity analyses.

Conclusions:

Among euthyroid adults, lower TSH and higher FT4 are associated with an increased risk of hip fracture. These findings may help refine the definition of optimal ranges of thyroid function tests.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiroxina / Tireotropina / Fraturas da Coluna Vertebral / Fraturas do Quadril Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tiroxina / Tireotropina / Fraturas da Coluna Vertebral / Fraturas do Quadril Idioma: En Ano de publicação: 2017 Tipo de documento: Article